Reduction Of Share Capital Due To Losses By Reduction Of Nominal Value: Number Of Shares Unchanged

(MENAFN- GlobeNewsWire - Nasdaq) English French

Reduction of share capital due to losses by reduction of nominal value: number of shares unchanged

Paris, France, March 17 , 2023 – 07:00 CET – The Board of Directors of the Company decided at its meeting of March 16, 2023, to implement the authorization granted to it by the General Meeting of March 8, 2023 pursuant to its First resolution and decided to reduce the share capital by an amount of 3,257,856.68 euros, motivated by losses1, by reducing the nominal value of each share from 0.06 euro to 0.02 euro.

This purely technical operation has neither impact on the stock market value of the shares of the Company nor on the number of shares of the Company in circulation. After this operation, the share capital amounting to 1,628,928.34 euros remains composed of 81,446,417 shares having a nominal value of 0.02 euro.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as“Entreprise Innovante” by Bpifrance.

For more information:

Follow us on @pixiumvision ;


Pixium Vision
Offer Nonhoff
Chief Financial Officer

+33 1 76 21 47 68
Media R elations
LifeSci Advisors
Sophie Baumont

+33 6 27 74 74 49
Investor R elation s
LifeSci Advisors
Guillaume van Renterghem

+41 76 735 01 31

1 The amount of the capital reduction was used to cover the Company's previous losses and the balance was allocated to an unavailable reserve account to cover future losses.


  • pixium vision - k decrease en v 15 03 2023

Tags amd dry-amd pixium vision prima prima system vision restoration visual acuity acuité visuelle dmla système prima Attachments Pixium Vision - K decrease EN v 15 03 2023...


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.